If this is where you are
Newly diagnosedReports arriving, no plan yetAlready tested elsewhereYou have results you cannot readOn treatment nowYou want to know it is workingOr
Finished treatmentWatching for anything left behindWorried about familyInherited risk, and relativesWanting a second opinionA decision you are unsure aboutDecide
Blueprint CareThe flagship decision report and a dedicated clinical teamSignalOne free question answered on WhatsApp within four hoursNavigationRecords you already have, turned into a clarity timelineDecipherInterpretation of sequencing already done elsewhereTest
Signature, all tiersSolid tumour and blood cancer panels comparedSignature STb33 genes from a blood drawSignature STb O118 genes from a blood drawSignature STb O+523 genes, with TMB and MSISignature STt OProfiling from an existing tissue blockMonitor
SentinelSerial monitoring while treatment is runningSentinel SolidctDNA monitoring for solid tumoursClearMolecular residual disease surveillanceClear SolidTumour-informed surveillanceProtect
HeritageInherited risk, assessed properlyHeritage CoreA broad inherited-risk assessmentHeritage AdhocFocused testing for named relativesCancer DictionaryWhat is discussed in your specific cancerReference
Cancer DictionaryOne structured entry per cancer typeBiomarker LibraryOne page per marker, in plain languagePatient ResourcesGlossary, guides and how to use themWatch, read and ask
Video LibraryShort explainers, captioned and translatedStoriesPatient and clinician experiences, consentedFAQThe questions we are asked mostCancer Dictionary · Genitourinary
Germ cell tumours of the testis are unusually responsive to treatment, and cure is the expected outcome in most cases including many with metastatic disease. Because of that, the central questions are about accurate risk classification, avoiding both undertreatment and unnecessary long-term toxicity, and fertility preservation. Genomic profiling plays a limited role.
Also called Germ cell tumour, Seminoma, Non-seminomatous germ cell tumour.
Start here
Testicular germ cell tumours are highly curable, which shifts the entire discussion from finding a target towards giving the right amount of treatment and preserving long-term health.
Germ cell tumours of the testis are unusually responsive to treatment, and cure is the expected outcome in most cases including many with metastatic disease. Because of that, the central questions are about accurate risk classification, avoiding both undertreatment and unnecessary long-term toxicity, and fertility preservation. Genomic profiling plays a limited role.
01Before any molecular question
Usually established first: histology (seminoma or non-seminomatous), stage, and serum tumour marker levels. The markers are unusually informative in this disease and are part of the staging system itself, not merely a monitoring tool. Fertility preservation is discussed before treatment begins, and the timing of that conversation matters.
Usually already established
02
The divisions below are not labels. Each one changes what the treatment discussion is actually about.
Seminoma
One of the two main histological groups, with its own management pathway.
Non-seminomatous germ cell tumour
Includes embryonal carcinoma, yolk sac tumour, choriocarcinoma and teratoma, alone or mixed.
Stage I disease
Where the discussion is often surveillance versus adjuvant treatment, weighing recurrence risk against long-term toxicity.
Metastatic disease
Classified into risk groups that determine treatment intensity. Cure remains the goal in all groups.
Platinum-refractory disease
Uncommon, and the situation where profiling and trials become more relevant.
03What is discussed
Isochromosome 12p is the characteristic cytogenetic finding across germ cell tumours and is used diagnostically, particularly where a tumour outside the testis is suspected to be of germ cell origin. Beyond this, germ cell tumours carry relatively few mutations. Comprehensive genomic profiling rarely changes management, and is discussed mainly in platinum-refractory disease or where the diagnosis is uncertain. Serum markers, though not genomic, are the molecular measurements that actually drive decisions in this disease.
AFP, hCG, LDH
Serum markers. Part of staging and central to monitoring, unusually so for a solid tumour.
Isochromosome 12p
The characteristic cytogenetic finding. Used to confirm germ cell origin.
TP53
Rarely altered, and its alteration is associated with platinum resistance.
microRNA-371a-3p
Under study as a more sensitive circulating marker than the conventional serum markers.
This is not an exhaustive list, and which markers are relevant depends on the individual case. Not every marker listed is assessed in every patient.
04What is tested, and from what
Genomic profiling is not part of routine management. Where it is discussed, the reasons are usually diagnostic uncertainty, an extragonadal presentation where germ cell origin needs confirming, or platinum-refractory disease where trial options are being sought.
A family history of testicular cancer raises risk, and a personal history of undescended testis is a recognised risk factor, but no single high-penetrance gene explains most cases. Formal germline testing is not a routine part of the pathway.
Cancer genetics and hereditary riskCirculating microRNA, particularly miR-371a-3p, is under active study as a marker more sensitive than conventional serum markers, with potential application to surveillance and residual disease. Conventional ctDNA has a smaller role here.
More on ctDNA monitoring05The timing question
Testing that arrives after the decision it was meant to inform has already been made is a common and avoidable problem. This is the sequence in which molecular information tends to become relevant.
06Take these to your team
When a decision is being made
Questions worth raising with a treating team.
At progression, recurrence or resistance
The molecular picture at diagnosis is not always the molecular picture later.
07What shapes eligibility
Trial activity is concentrated in platinum-refractory disease and in de-escalation strategies aimed at reducing long-term toxicity while preserving cure rates. The second category is distinctive: much of the research effort here is about giving less, not more.
| Term | What it means |
|---|---|
| Seminoma | One of the two main germ cell tumour types, with a distinct treatment pathway. |
| Teratoma | A germ cell tumour component that does not respond to chemotherapy and may need surgical removal. |
| Serum tumour markers | Blood proteins that reflect disease activity. In this cancer they form part of the staging system. |
| De-escalation | Reducing treatment intensity to lower long-term harm while keeping cure rates. |
| Late effects | Health consequences appearing years after treatment. Central to decisions in a young, curable population. |
These are the services most often relevant to this cancer. Which of them applies is a clinical question, not an automatic one.
This entry is educational. It describes what is commonly discussed in this cancer, not what should happen for any individual. Which of it applies depends on the specific diagnosis, stage, prior treatment and the person themselves. Nothing here is a recommendation, and no list of biomarkers here is exhaustive. Decisions belong with a treating team who know the whole case.
Take the next step
A no-obligation conversation with our care team, arranged through KPCIRC.
Book a consultationCommission your decision report and a dedicated clinical team.
Explore Blueprint CareSignal replies to your first question within four hours, at no cost.
Start with Signal